The Assessment of Antimicrobial Peptides Against Fungal Infection

May 6, 2022 updated by: Sara salah abd El mawgoud, Assiut University
  • Identification of different types of fungi.
  • Determine sensitivity the profile and the resistance pattern of the clinical isolates against antifungal.
  • Determine the antifungal effects of defensin, cathelicidin and histatins and their effects on biofilm formation and resistant isolates.

Study Overview

Status

Not yet recruiting

Conditions

Detailed Description

Fungal infections are recurrent in the clinical environment and, annually, affect 25% of the general population worldwide, causing high morbidity and mortality rates. The indiscriminate use of broad-spectrum antibiotics, along with parenteral nutrition, permanent catheters, chemotherapy and radiotherapy, as well as immunosuppression in patients, is the most important predisposing factors for invasive fungal infections. Fungi are classified according to their morphologies, including yeasts (Cryptococcus spp.), fungi with branched hyphae (Aspergillus spp.), as well as fungi with both morphologies (yeasts and pseudohyphae, as for Candida spp.), which have all been associated with fungal infections in humans.

Fungal biofilms are communities of adherent cells surrounded by an extracellular matrix. These biofilms are commonly found during infection caused by a variety of fungal pathogens. Clinically, biofilm infections can be extremely difficult to eradicate due to their resistance to antifungals and host defenses. Biofilm formation can protect fungal pathogens from many aspects of the innate immune system, including killing by neutrophils and monocytes. Currently, antifungal therapies are scarce and include only four classes of antifungal agents, polyenes, triazoles, echinocandins and flucytosine . The misuse of antifungal agents over the last two decades contributed to antifungal resistance development.Fungal resistance emergence has important clinical implications, as it limits the already small arsenal of antifungal agents, raising the idea of a "post-antifungal" era. Antimicrobial peptides (AMPs) have emerged as new biopharmaceuticals to prevent or treat fungal infections. AMPs are a class of small peptides that widely exist in nature and are an important part of the innate immune system of different organisms. AMPs have a wide range of inhibitory effects against bacteria, fungi, parasites and viruses . Defensins comprise antifungal peptides isolated from various organisms, including plants and mammals . Plant defensins are cationic and have 45-54 amino acids in length. These peptides have typically been isolated from seeds, but can also be found in other plant tissues including leaves, flowers, roots and stems. Most of the plant defensins identified so far have eight cysteine residues that favor structural stability by the formation of four disulfide bonds . In addition, structural studies have shown that plant defensins comprise a triple β-sheet with a parallel helix. Regarding their biological properties, plant defensins have shown activity against bacteria and fungi, both in their planktonic and biofilm modes of growth . Peptides from the cathelicidin family have been isolated from different species of mammals and exhibit broad-spectrum activities against fungi. Cathelicidins are characterized as cationic peptides, consisting of 12-80 amino acids that adopt an α-helix or β-sheet as secondary structures, most of which have 23-37 amino acid residues distributed in amphipathic helices, including LL-37. The activities of LL-37 have been investigated against Candida spp. strains. Human salivary histatins are a group of small histidine-rich proteins constituted from 7 to 38 amino acids first isolated from human parotid saliva. In general, histatins are a multifunctional group of proteins with antimicrobial properties that vary from broad-spectrum to moderate activities. Moreover, histatins have been reported for their effective antifungal activity

Study Type

Observational

Enrollment (Anticipated)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: sara salah abd el mawgoud, assistant lecturer
  • Phone Number: 01092127787
  • Email: fawazsara@gmail.com

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 70 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

- Samples obtained from patients with cutaneous fungal infection and systemic fungal infection

Description

Inclusion Criteria:

  • - Samples obtained from patients with cutaneous fungal infection and systemic fungal infection

Exclusion Criteria:

  • Patients diagnosed to be viral or bacterial infections.
  • Patients on antibiotic or antifungal treatment

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
1.to determine the level at which inhibition of fungi occurs
Time Frame: 6 months
Determination of defensin ,cathelicidin and histatin is done using broth microdilution method . The procedure involves preparation of twofold dilutions in sterile heart brain broth inside the wells of 96-well microplate.The highest dilution of samples without visible growth after 24 h incubation at 37 °C was considered as minimum inhibitory concentration. . A change in color from blue to pink indicates the growth of bacteria .
6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
measure the percentage of decrease in biofilm formation
Time Frame: 6 month
The ability of fungal isolates to adhere and to form biofilms in a 96-well plate will be done using the microtiter plate assay.
6 month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Director: amal mohamad hosni, lecturer, Assiut University
  • Study Chair: asmaa omar ahmed, assistant professor, Assiut University
  • Study Chair: mohamad zakaria abd elrahman, professor, Assiut University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ANTICIPATED)

December 1, 2022

Primary Completion (ANTICIPATED)

February 1, 2023

Study Completion (ANTICIPATED)

June 1, 2023

Study Registration Dates

First Submitted

April 14, 2022

First Submitted That Met QC Criteria

May 6, 2022

First Posted (ACTUAL)

May 10, 2022

Study Record Updates

Last Update Posted (ACTUAL)

May 10, 2022

Last Update Submitted That Met QC Criteria

May 6, 2022

Last Verified

May 1, 2022

More Information

Terms related to this study

Other Study ID Numbers

  • antimicrobial peptides

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.